Hepatitis C News

Mavyret demonstrated high rates of safety and efficacy among patients with hepatitis C genotypes 1 and 4 who had previously been treated with other direct-acting antivirals, according to a recently published study.

An important barrier to hepatitis elimination is the upfront costs, which may be subverted with a range of financing mechanisms, according to data from international economic analyses presented at the World Hepatitis Summit 2017.

Using direct-acting antiviral therapies demonstrated similarly high rates of sustained virologic response for hepatitis C virus infection in patients with and without HIV infection as compared with rates for HCV mono-infected patients, according to findings published in Hepatology.

We are witnessing history. The explosion of new drugs into the hepatitis C marketplace has been both breathtaking and transformative. But, in HCV, we have peaked. Everything that happened in HCV, happened faster and more intensively than HIV but it follows the same storyline, with one exception: Drug pricing matters in HCV.

The Society for Maternal-Fetal Medicine recently issued its first-ever recommendations for pregnant women with hepatitis C — a segment of population that data suggest impacts 4% of pregnant women in the United States.

WASHINGTON — The combination of Merck’s ruzasvir and uprifosbuvir correlated with reduced efficacy in patients with hepatitis C genotype 3 with or without cirrhosis, according to a presentation at The Liver Meeting 2017.

Recent data revealed that, worldwide, 52 million children are living with viral hepatitis, compared with 2.1 million children with HIV or AIDS, according to data presented at the World Hepatitis Summit 2017 in São Paulo, Brazil.

Generic direct-acting antiviral regimens for hepatitis C can be manufactured for $50 and are as effective as branded medicines, according to data presented at the World Hepatitis Summit 2017 in São Paulo, Brazil.

Australia, Brazil, Egypt, Georgia, Germany, Iceland, Japan, the Netherlands and Qatar are on course to eradicate hepatitis C by 2030, according to data presented at the World Hepatitis Summit in Brazil.

More than half of the estimated 2.7 million people with hepatitis C in the U.S. are unaware of their infection, which contributes to increased transmission rates and poor treatment outcomes, according to data presented at the World Hepatitis Summit 2017 in São Paulo, Brazil.